Effects of TACE combined with precise RT on p53 gene expression and prognosis of HCC patients

Liu,Yupeng; Yan,Jingchen; Wang,Feng

doi:10.3892/ol.2018.9374

Effects of TACE combined with precise RT on p53 gene expression and prognosis of HCC patients

Authors:
- Yupeng Liu
- Jingchen Yan
- Feng Wang
View Affiliations

Affiliations: Department of Emergency, The First People's Hospital of Qinhuangdao, The Affiliated Hospital of Hebei Medical University, Qinhuangdao, Hebei 066000, P.R. China, Department of Intervention, Liaocheng Cancer Hospital, Liaocheng, Shandong 252000, P.R. China, Department of Nuclear Medicine, The First Hospital of Shijiazhuang, Shijiazhuang, Hebei 050011, P.R. China
Published online on: August 30, 2018 https://doi.org/10.3892/ol.2018.9374
Pages: 5733-5738
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To investigate the effects of transcatheter arterial chemoembolization (TACE) combined with precise radiation therapy (RT) on p53 gene expression and prognosis of patients with hepatocellular carcinoma (HCC). A total of 80 patients with unresectable HCC treated in the First People's Hospital of Qinhuangdao from March 2009 to March 2015 were randomly divided into TACE group (n=40) and TACE + RT group (n=40). Enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of p53 in both groups before and after treatment. The biochemical indexes of liver function [α-fetoprotein (AFP), alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT)] were detected. Moreover, adverse reactions were compared between the two groups of patients, the short-term therapeutic effect was evaluated, and effects of two treatment methods on progression-free survival (PFS) and overall survival (OS) of patients were detected. There were no statistically significant differences in clinical data between the two groups of patients (P>0.05). The p53 protein levels were significantly downregulated in both treatment methods, and it was decreased more significantly in TACE + RT group than that in TACE group (P<0.05). Compared with those before treatment, AFP and GGT levels in both groups of patients after treatment were decreased, but the levels of ALT were increased (P<0.05), and TACE + RT group had a better curative effect than TACE group (P<0.05). Besides, the incidence rate of adverse reactions in TACE + RT group (37.5%) was obviously lower than that in TACE group (65%) (P<0.05). The number of patients with stable disease (SD) and progressive disease (PD) and disease control rate (DCR) in TACE + RT group were superior to those in TACE group (P<0.05). The 2-year survival rate and median PFS of patients in TACE + RT group were also significantly better than those in TACE group (P<0.05). In conclusion, TACE combined with RT has a better clinical effect than TACE alone in the treatment of HCC.

View Figures

View References

1	Halliday J, Helmy K, Pattwell SS, Pitter KL, LaPlant Q, Ozawa T and Holland EC: In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. Proc Natl Acad Sci USA. 111:pp. 5248–5253. 2014; View Article : Google Scholar : PubMed/NCBI
2	Oishi N, Yamashita T and Kaneko S: Molecular biology of liver cancer stem cells. Liver Cancer. 3:71–84. 2014. View Article : Google Scholar : PubMed/NCBI
3	Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM, et al: Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 122:1312–1337. 2016. View Article : Google Scholar : PubMed/NCBI
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
5	Zhang Y, Liu S, Wang X, Zhang Z, Jing X, Zhang P and Xie Z: Prevention of local liver cancer recurrence after surgery using multilayered cisplatin-loaded polylactide electrospun nanofibers. Chin J Polym Sci. 8:1111–1118. 2014. View Article : Google Scholar
6	Bruix J, Han KH, Gores G, Llovet JM and Mazzaferro V: Liver cancer: Approaching a personalized care. J Hepatol. 62 Suppl 1:S144–S156. 2015. View Article : Google Scholar : PubMed/NCBI
7	Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, Di Sarno A, Carratù AC, de Luca di Roseto C, Colao A, et al: Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 47:177–182. 2014. View Article : Google Scholar : PubMed/NCBI
8	Lee DS and Seong J: Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis. Liver Cancer. 3:18–30. 2014. View Article : Google Scholar : PubMed/NCBI
9	Im JH, Yoon SM, Park HC, Kim JH, Yu JI, Kim TH, Kim JW, Nam TK, Kim K, Jang HS, et al: Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. Liver Int. 37:90–100. 2017. View Article : Google Scholar : PubMed/NCBI
10	Phillips WT, Bao A, Brenner AJ and Goins BA: Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles. Adv Drug Deliv Rev. 76:39–59. 2014. View Article : Google Scholar : PubMed/NCBI
11	Freed-Pastor W and Prives C: Targeting mutant p53 through the mevalonate pathway. Nat Cell Biol. 18:1122–1124. 2016. View Article : Google Scholar : PubMed/NCBI
12	Muller PA and Vousden KH: p53 mutations in cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar : PubMed/NCBI
13	Muller PA and Vousden KH: Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
14	Lencioni R and Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 1:52–60. 2010. View Article : Google Scholar
15	Xia J, Ren Z, Ye S, Sharma D, Lin Z, Gan Y, Chen Y, Ge N, Ma Z, Wu Z, et al: Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol. 59:407–412. 2006. View Article : Google Scholar : PubMed/NCBI
16	Jihye C and Jinsil S: Application of radiotherapeutic strategies in the BCLC-defined stages of hepatocellular carcinoma. Liver Cancer. 1:216–225. 2012. View Article : Google Scholar : PubMed/NCBI
17	Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, Höss A, Schlegel W and Wannenmacher MF: Stereotactic single-dose radiation therapy of liver tumors: Results of a phase I/II trial. J Clin Oncol. 19:164–170. 2001. View Article : Google Scholar : PubMed/NCBI
18	Salem R, Thurston KG, Carr BI, Goin JE and Geschwind JF: Yttrium-90 microspheres: Radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 13:S223–S229. 2002. View Article : Google Scholar : PubMed/NCBI
19	Matsuura M, Nakajima N, Arai K and Ito K: The usefulness of radiation therapy for hepatocellular carcinoma. Hepatogastroenterology. 45:791–796. 1998.PubMed/NCBI
20	Seong J, Keum KC, Han KH, Lee DY, Lee JT, Chon CY, Moon YM, Suh CO and Kim GE: Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 43:393–397. 1999. View Article : Google Scholar : PubMed/NCBI
21	Jung WS and Shin RM: The effect of patient position on dose in radiation therapy of liver cancer. J Korean Soc Radiotherapeutic Technol. 1:1–9. 2014.
22	Roake CM and Artandi SE: Control of cellular aging, tissue function, and cancer by p53 downstream of telomeres. Cold Spring Harb Perspect Med. 7:260882017. View Article : Google Scholar
23	Smet FD, Rubio M and Hompes S: Nuclear inclusion bodies of mutant and wild-type p53 in cancer: A hallmark of p53 inactivation and proteostasis remodeling by p53 aggregation. J Pathol. 2:875–882. 2016.
24	Rahman M, Lovat F, Romano G, Calore F, Acunzo M, Bell EH and Nana-Sinkam P: miR-15b/16-2 regulates factors that promote p53 phosphorylation and augments the DNA damage response following radiation in the lung. J Biol Chem. 289:26406–26416. 2014. View Article : Google Scholar : PubMed/NCBI
25	Rubner Y, Muth C, Strnad A, Derer A, Sieber R, Buslei R, Frey B, Fietkau R and Gaipl US: Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines. Radiat Oncol. 9:892014. View Article : Google Scholar : PubMed/NCBI